# A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

> **NCT06460961** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 168 (estimated)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **BIOLOGICAL:** MK-6837
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Rescue Medications

## Key facts

- **NCT ID:** NCT06460961
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-14
- **Primary completion:** 2027-07-13
- **Final completion:** 2027-07-13
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06460961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06460961, "A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06460961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*